Alar Pharmaceuticals
6785.TWO
3.85 USD
0.01
+0.26%
a
Overview
Last close
3.85 usd
Market cap
257.21M usd
52 week high
14.52 usd
52 week low
3.82 usd
Target price
8.86 usd
Valuation
P/E
17.8977
Forward P/E
N/A
Price/Sales
17.9359
Price/Book Value
3.3982
Enterprise Value
182.13M usd
EV/Revenue
12.565
EV/EBITDA
14.019
Key financials
Revenue TTM
14.34M usd
Gross Profit TTM
14.34M usd
EBITDA TTM
11.75M usd
Earnings per Share
0.22 usd
Dividend
N/A usd
Total assets
78.46M usd
Net debt
-20.81M usd
About
Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. It is developing ALA-1000, which is in Phase II clinical trials for the treatment of opioid use disorder; ALA-1300 and ALA-2000, which is in pre-clinical stage for opioid use disorder; ALA-4000 which is in pre-clinical stage for treatment of Parkinson's disease; and ALA-3000, which is in pre-clinical stage for treating treatment-resistant depression. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.
- Symbol6785.TWO
- ExchangeTWO
- IsinN/A
- CountryTaiwan
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CEODr. Yung-Shun Wen Ph.D.
- HeadquarterTaichung
- Web sitehttps://www.alarpharm.com
